Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.79 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | RAF1 | P04049 | 1/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3635259 | 0.91 | MAPK14 (0.79) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3640728 | 0.89 | MAPK14 (0.79) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3668926 | 0.85 | MAPK14 (1.00) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3767675 | 0.83 | MAPK14 (0.78) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3637436 | 0.83 | MAPK14 (0.82) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3634954 | 0.81 | MAPK14 (1.00) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3671303 | 0.77 | MAPK14 (0.70) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3762600 | 0.77 | MAPK14 (0.66) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3673309 | 0.76 | MAPK14 (0.58) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3638251 | 0.76 | MAPK14 (1.00) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846944-B2 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2010-12-07 | — | — | US | disclosed |
| EP-2152704-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | Amgen, Inc (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | AMGEN INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008137176-A1 | PYRAZOLO-PYRIDINONE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012299-A1 | Pyrazolo-pyridinone compounds and methods of use thereof | MAPK1, MAP3K1, MAP4K2 | MAPK14 41/4885MAPKAPK2 29/4885MAPK13 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.